NO993647L - Endotelinantagonist - Google Patents

Endotelinantagonist

Info

Publication number
NO993647L
NO993647L NO993647A NO993647A NO993647L NO 993647 L NO993647 L NO 993647L NO 993647 A NO993647 A NO 993647A NO 993647 A NO993647 A NO 993647A NO 993647 L NO993647 L NO 993647L
Authority
NO
Norway
Prior art keywords
endothelin antagonist
endothelin
antagonist
keto
dihalo
Prior art date
Application number
NO993647A
Other languages
English (en)
Other versions
NO328460B1 (no
NO993647D0 (no
Inventor
Ryuji Ueno
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Publication of NO993647D0 publication Critical patent/NO993647D0/no
Publication of NO993647L publication Critical patent/NO993647L/no
Publication of NO328460B1 publication Critical patent/NO328460B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO19993647A 1997-11-28 1999-07-27 Anvendelse av 15-keto-prostaglandin E-forbindelser til fremstilling av medikamenter NO328460B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP32783297 1997-11-28
PCT/JP1998/005143 WO1999027934A1 (fr) 1997-11-28 1998-11-16 Antagoniste d'endotheline

Publications (3)

Publication Number Publication Date
NO993647D0 NO993647D0 (no) 1999-07-27
NO993647L true NO993647L (no) 1999-09-27
NO328460B1 NO328460B1 (no) 2010-02-22

Family

ID=18203488

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19993647A NO328460B1 (no) 1997-11-28 1999-07-27 Anvendelse av 15-keto-prostaglandin E-forbindelser til fremstilling av medikamenter

Country Status (17)

Country Link
US (1) US6197821B1 (no)
EP (1) EP0978284B1 (no)
JP (1) JP4319256B2 (no)
KR (1) KR100648868B1 (no)
CN (1) CN1206997C (no)
AT (1) ATE401894T1 (no)
AU (1) AU739343B2 (no)
CA (1) CA2279267C (no)
DE (1) DE69839767D1 (no)
DK (1) DK0978284T3 (no)
ES (1) ES2310013T3 (no)
HK (1) HK1025521A1 (no)
NO (1) NO328460B1 (no)
NZ (1) NZ336960A (no)
PT (1) PT978284E (no)
TW (1) TW592701B (no)
WO (1) WO1999027934A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2458471C (en) * 2001-08-31 2012-07-31 Sucampo Ag Prostaglandin analogs as chloride channel opener
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) * 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
MXPA05006981A (es) * 2002-12-27 2005-12-14 Sucampo Ag Derivados de prostaglandinas para el tratamiento de la molestia abdominal.
US20040225014A1 (en) * 2003-02-14 2004-11-11 Sucampo Ag Method for treating ocular hypertension and glaucoma
WO2006080549A2 (en) * 2005-01-27 2006-08-03 Sucampo Ag Method and composition for treating central nervous system disorders
CN103919783A (zh) 2005-03-04 2014-07-16 苏坎波公司 治疗外周血管病的方法和组合物
CN103755737A (zh) * 2006-02-07 2014-04-30 株式会社·R-技术上野 用于制备前列腺素衍生物的方法
TWI422368B (zh) * 2006-02-28 2014-01-11 Sucampo Ag 治療慢性阻塞性肺疾之組成物
US20100022568A1 (en) * 2006-04-13 2010-01-28 Actelion Pharmaceeuticals Ltd. Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
US20080207759A1 (en) * 2007-02-27 2008-08-28 Sucampo Ag Method for protecting mitochondria
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
CN102050808B (zh) * 2009-11-02 2014-03-12 上海天伟生物制药有限公司 一种前列腺素中间体的制备方法
EP2516412A4 (en) * 2009-12-18 2013-05-29 Apotex Pharmachem Inc PROCESS FOR CLEANING LUBIPROSTON
CN104557845B (zh) * 2015-01-13 2020-12-22 齐鲁制药有限公司 一种鲁比前列酮化合物的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853951A (en) 1971-07-14 1974-12-10 American Cyanamid Co Preparation of 9-oxo-13-trans-prostenoic acid esters by alanate addition to cyclopentenone
US4018811A (en) 1972-02-11 1977-04-19 American Cyanamid Company 3-Alkyl-2-(6-carboxyhexyl)cyclopentanones and esters and salts thereof
US3981868A (en) 1973-05-31 1976-09-21 American Cyanamid Company Derivatives of 9-oxo-13-trans-prostenoic acid amides
CA1323364C (en) * 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
US5362751A (en) 1988-05-11 1994-11-08 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Tracheobronchodilator using 16-substituted PGEs
JP2597649B2 (ja) * 1988-05-11 1997-04-09 株式会社上野製薬応用研究所 気管・気管支拡張剤
EP0343904B1 (en) 1988-05-23 1993-04-28 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Hypersphyxia causing composition
JPH0232031A (ja) * 1988-07-22 1990-02-01 Nippon Steel Chem Co Ltd イソプロピル化ｐ‐ターフェニル類の製造法
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2030346C (en) * 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
TW224942B (no) 1990-04-04 1994-06-11 Adka Ueno Kk
DE69130586T2 (de) * 1990-05-01 1999-06-17 R Tech Ueno Ltd Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
CA2046069C (en) 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
EP0503887B1 (en) * 1991-03-14 1996-08-28 R-Tech Ueno Ltd. Promotion of wound-healing with 15-keto-prostaglandin compounds
KR19990036322A (ko) 1996-06-10 1999-05-25 류지 우에노 엔도텔린길항제
JPH107574A (ja) 1996-06-17 1998-01-13 R Tec Ueno:Kk エンドセリン拮抗剤

Also Published As

Publication number Publication date
TW592701B (en) 2004-06-21
ES2310013T3 (es) 2008-12-16
CN1251040A (zh) 2000-04-19
EP0978284A1 (en) 2000-02-09
NO328460B1 (no) 2010-02-22
ATE401894T1 (de) 2008-08-15
DE69839767D1 (de) 2008-09-04
NZ336960A (en) 2001-02-23
US6197821B1 (en) 2001-03-06
WO1999027934A1 (fr) 1999-06-10
KR20000070508A (ko) 2000-11-25
HK1025521A1 (en) 2000-11-17
JP4319256B2 (ja) 2009-08-26
AU1053799A (en) 1999-06-16
DK0978284T3 (da) 2008-10-27
EP0978284B1 (en) 2008-07-23
CA2279267C (en) 2010-01-12
PT978284E (pt) 2008-10-07
NO993647D0 (no) 1999-07-27
AU739343B2 (en) 2001-10-11
CN1206997C (zh) 2005-06-22
CA2279267A1 (en) 1999-06-10
KR100648868B1 (ko) 2006-11-24
EP0978284A4 (en) 2001-07-18

Similar Documents

Publication Publication Date Title
NO993647L (no) Endotelinantagonist
FI20050238A (fi) Markfortiini- ja paraherkvamidiyhdisteet
SV1996000005A (es) Quinazolinonas bisustituidas en 2,8
EA200000381A1 (ru) Препарат 2-метил-тиено-бензодиазепина
FR09C0028I2 (fr) ANTAGONISTES DE GnRH MODIFIES AUX POSITIONS 5 ET 6
CY2007024I1 (el) Kαινοφανη παραγωγα 3.3-διαφαινυλοπροπυλινων
FR2704135B1 (fr) Agrafe d'osteosynthese.
JP2000500076A5 (no)
JP2000500055A5 (no)
JP2000500026A5 (no)
JP2000500874A5 (no)
ATE314387T1 (de) Dolastatin 15 derivate
JP2000500318A5 (no)
JP2000500184A5 (no)
FR2750610B3 (fr) Palme constituee par la combinaison d'une botte, d'une chaussure, d'un soulier ou similaire avec une palme
TR199501132A2 (tr) Nörokinin karsitlari (antagonistleri).
ID28874A (id) Inhibitor fosfodiesterase 4 turunan ftalazina.
BR9804027A (pt) Novos beta-ceto ésteres
JP2000500662A5 (no)
TR199800988A3 (tr) 5' Deoksi-Sitidin türevleri.
DE69938258D1 (de) 4,5-pyrazinoxindole als proteinkinasehemmer
PT1119359E (pt) Formulacao de 2-metil-tieno-benzodiazepina
IT1302243B1 (it) Sintesi dell'1,1,1,3,3-pentafluoropropano.
ATE251457T1 (de) Substituierte 1,2,3,4-tetrahydro-2- dibenzofuranamine und 2- aminocyclohepta(b)benzofurane
BR0114065A (pt) Triazolo-epotilonas

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees